TimesSquare Capital Management LLC Increases Stock Holdings in DexCom, Inc. (NASDAQ:DXCM)

TimesSquare Capital Management LLC grew its holdings in DexCom, Inc. (NASDAQ:DXCM) by 4.8% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 768,590 shares of the medical device company’s stock after buying an additional 35,210 shares during the quarter. DexCom comprises 1.4% of TimesSquare Capital Management LLC’s investment portfolio, making the stock its 15th biggest holding. TimesSquare Capital Management LLC’s holdings in DexCom were worth $95,374,000 as of its most recent SEC filing.

Several other hedge funds have also modified their holdings of DXCM. Stableford Capital II LLC raised its holdings in DexCom by 2.1% during the fourth quarter. Stableford Capital II LLC now owns 4,367 shares of the medical device company’s stock worth $563,000 after purchasing an additional 88 shares during the last quarter. Valley National Advisers Inc. grew its position in shares of DexCom by 73.0% in the fourth quarter. Valley National Advisers Inc. now owns 244 shares of the medical device company’s stock valued at $30,000 after purchasing an additional 103 shares during the period. FORVIS Wealth Advisors LLC grew its position in DexCom by 0.7% during the fourth quarter. FORVIS Wealth Advisors LLC now owns 16,381 shares of the medical device company’s stock valued at $2,033,000 after acquiring an additional 110 shares during the period. Cary Street Partners Investment Advisory LLC lifted its stake in shares of DexCom by 11.1% during the third quarter. Cary Street Partners Investment Advisory LLC now owns 1,153 shares of the medical device company’s stock worth $108,000 after purchasing an additional 115 shares in the last quarter. Finally, HM Payson & Co. lifted its stake in shares of DexCom by 8.5% in the third quarter. HM Payson & Co. now owns 1,480 shares of the medical device company’s stock worth $138,000 after acquiring an additional 116 shares in the last quarter. 97.75% of the stock is owned by institutional investors and hedge funds.

DexCom Trading Up 0.6 %

NASDAQ DXCM traded up $0.72 during trading on Thursday, reaching $128.14. 1,464,245 shares of the stock traded hands, compared to its average volume of 2,964,416. The firm has a market cap of $50.96 billion, a price-to-earnings ratio of 82.67, a price-to-earnings-growth ratio of 2.19 and a beta of 1.23. The stock’s 50-day moving average price is $133.20 and its 200 day moving average price is $121.21. The company has a quick ratio of 2.53, a current ratio of 2.90 and a debt-to-equity ratio of 1.08. DexCom, Inc. has a fifty-two week low of $74.75 and a fifty-two week high of $142.00.

DexCom (NASDAQ:DXCM) last announced its quarterly earnings results on Thursday, April 25th. The medical device company reported $0.32 earnings per share for the quarter, beating analysts’ consensus estimates of $0.27 by $0.05. DexCom had a net margin of 16.82% and a return on equity of 31.01%. The firm had revenue of $921.00 million for the quarter, compared to analyst estimates of $911.20 million. Analysts predict that DexCom, Inc. will post 1.78 EPS for the current year.

Insider Buying and Selling at DexCom

In other news, CFO Jereme M. Sylvain sold 3,363 shares of the business’s stock in a transaction on Tuesday, February 20th. The shares were sold at an average price of $116.73, for a total value of $392,562.99. Following the sale, the chief financial officer now owns 71,142 shares of the company’s stock, valued at $8,304,405.66. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. In related news, EVP Sadie Stern sold 20,321 shares of the firm’s stock in a transaction dated Tuesday, March 12th. The shares were sold at an average price of $133.61, for a total transaction of $2,715,088.81. Following the transaction, the executive vice president now directly owns 80,441 shares of the company’s stock, valued at $10,747,722.01. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CFO Jereme M. Sylvain sold 3,363 shares of the firm’s stock in a transaction dated Tuesday, February 20th. The stock was sold at an average price of $116.73, for a total transaction of $392,562.99. Following the transaction, the chief financial officer now directly owns 71,142 shares in the company, valued at $8,304,405.66. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 190,004 shares of company stock valued at $25,610,270. 0.41% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

Several research firms recently commented on DXCM. Raymond James boosted their price target on DexCom from $151.00 to $160.00 and gave the stock a “strong-buy” rating in a research note on Friday, April 26th. StockNews.com downgraded DexCom from a “buy” rating to a “hold” rating in a report on Thursday. UBS Group raised their price objective on DexCom from $153.00 to $163.00 and gave the stock a “buy” rating in a research note on Wednesday, April 10th. Royal Bank of Canada initiated coverage on shares of DexCom in a research report on Tuesday, March 12th. They set an “outperform” rating and a $165.00 price objective for the company. Finally, Canaccord Genuity Group upped their target price on shares of DexCom from $144.00 to $145.00 and gave the stock a “buy” rating in a research report on Friday, April 26th. Three analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $141.67.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.